Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 27, 2008, Pages 4449-4457

  Dunnwald, Lisa K ^a   Gralow, Julie R ^a   Ellis, Georgiana K ^a   Livingston, Robert B ^a   Linden, Hannah M ^a   Specht, Jennifer M ^a   Doot, Robert K ^a   Lawton, Thomas J ^a   Barlow, William E ^a   Kurland, Brenda F ^a   Schubert, Erin K ^a   Mankoff, David A ^a  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; METHOTREXATE; NAVELBINE; OXYGEN 15; PACLITAXEL; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLISM; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR BLOOD FLOW;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREMEDICATION; RISK ASSESSMENT; SURVIVAL RATE;

EID: 52449103839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4385     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Feldman LD, Hortobagyi GN, Buzdar AU, et al: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986
3. Machiavelli MR, Romero AO, Perez JE, et al: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125-131, 1998
4. Kuerer HM, Newman LA, Buzdar AU, et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176:502-509, 1998
5. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
6. Rousseau C, Devillers A, Sagan C, et al: Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366-5372, 2006
7. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
8. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
9. Mankoff DA, Dunnwald LK, Gralow JR, et al: Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 43:500-509, 2002
10. Mankoff DA, Dunnwald LK, Gralow JR, et al: Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44:1806-1814, 2003
11. 18F-FDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45:1829-1837, 2004
12. Zasadny KR, Tatsumi M, Wahl RL: FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30:274-280, 2003
13. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997): Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803-1804, 1997
14. Lewellen TK, Kohlmyer S, Miyaoka R, et al: Investigation of the count rate performance of the General Electric ADVANCE positron emission tomograph. IEEE Trans Nucl Sci 42:1051-1057, 1995
15. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1986
16. 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 48:920-925, 2007
17. Social Security Administration: Social Security Death Index. http://www.socialsecurity.gov/
18. Parl FF, Schmidt BP, Dupont WD, et al: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54:2237-2242, 1984
19. McCready DR, Hortobagyi GN, Kau SW, et al: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124:21-25, 1989
20. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
21. Donegan WL: Prognostic factors: Stage and receptor status in breast cancer. Cancer 70:1755-1764, 1992
22. Pinder SE, Wencyk P, Sibbering DM, et al: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995
23. Fisher ER, Anderson S, Tan-Chiu E, et al: Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91:1679-1687, 2001
24. Li CI, Moe RE, Daling JR: Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 163:2149-2153, 2003
25. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
26. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). New York, NY, John Wiley & Sons, 2002
27. Eary JF, O'Sullivan F, Powitan Y, et al: Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 29:1149-1154, 2002
28. Flamen P, Van Cutsem E, Lerut A, et al: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361-368, 2002
29. 18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39:170-177, 2003
30. MacManus MP, Hicks RJ, Matthews JP, et al: Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285-1292, 2003
31. 18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 24:3026-3031, 2006
32. 18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 12:6437-6443, 2006
33. Vranjesevic D, Filmont JE, Meta J, et al: Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 43:325-329, 2002
34. Mankoff DA, Dunnwald LK, Gralow JR, et al: Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium-99m]-sestamibi scintimammography. Cancer 85:2410-2423, 1999
35. Esserman L, Kaplan E, Partridge S, et al: MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8:549-559, 2001
36. Kedar RP, Cosgrove DO, Smith IE, et al: Breast carcinoma: Measurement of tumor response to primary medical therapy with color flow Doppler imaging. Radiology 190:825-830, 1994
37. Abraham DC, Jones RC, Jones SE, et al: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91-100, 1996
38. Gilles R, Guinebretiere JM, Toussaint C, et al: Locally advanced breast cancer: Contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191:633-638, 1994
39. Semple SI, Gilbert FJ, Redpath TW, et al: The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14:2038-2045, 2004
40. Semple SI, Staff RT, Heys SD, et al: Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17:1393-1398, 2006
41. 99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103:680-688, 2005
42. Wedam SB, Low JA, Yang SX, et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777, 2006
43. Beaulieu S, Kinahan P, Tseng J, et al: SUV varies with time after injection in (18)F-FDG PET of breast cancer: Characterization and method to adjust for time differences. J Nucl Med 44:1044-1050, 2003
44. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-1066, 2006